-+ 0.00%
-+ 0.00%
-+ 0.00%

MOONLAKE IMMUNOTHERAPEUTICS SHARES UP 21% AFTER RIVAL ABBVIE REPORTS SKIN DRUG TRIAL DATA

Reuters·10/22/2026 16:02:12